孟鲁司特和布地奈德治疗支气管哮喘的研究

Observation of the effect of montelukast and budesonide on bronchial asthma

目的探讨孟鲁司特和布地奈德治疗支气管哮喘的临床疗效。方法将102例轻、中度支气管哮喘患者随机分为4组:A组(24例)每次服用孟鲁司特10mg,每晚1次。B组(28例)每次吸入布地奈德400μg,每天2次。C组(24例)每次吸入布地奈德400μg,每天2次;加用孟鲁司特10mg,每晚1次。D组(26例)每次吸入布地奈德800μg,每天2次。结果4组治疗后气道反应性的组胺浓度(PC20)评价指标均明显增加,差异均有统计学意义(P<0.05)。其中C组治疗后评价指标改善比其他各组更明显,差异有统计学意义(P<0.05)。C组和D组治疗后肺功能指标均高于治疗前,差异有统计学意义(P<0.05);且改善情况优于A组和B组,差异均有统计学意义(P<0.05)。结论孟鲁司特联合吸入布地奈德治疗轻、中度支气管哮喘效果显著,可减少肾上腺糖皮质激素用量。

Objective To assess the clinical effect of montelukast and budesonide on bronchial asthma. Methods 102 cases with mild to moderate bronchial asthma were randomly divided into 4 group. Montelukast was given （ oral dosage,10mg, once a day）in group A. Inhaled corticosteroid budesonide was given（400μg, once a day）in group B. Inhaled corticosteroid budesonide was given （400μg, once a day）, and Montelukast was given （ oral dosage, 10mg, once a day） in group C. Inhaled corticosteroid budesonide was given（800μg, once a day）in group D. Results After treatment,the airway responsiveness histamine concentration（PC20） were significantly higher, the differences were statistically significant（ P 〈 0.05 ）, the situation improved of group C was better than the other groups, the differences were statistically significant （ P 〈 0.05 ） ; The lun function of group C and group D were higher than before treatment, the differences were statistically siginficact （ P 〈 0.05 ）, and the stua- tian improved were better than group A and group B, the differences were statistically significant （ P 〈 0.05 ）. Conclusion Montelukast and budesonide could improve mild to moderate asthma in patients with dyspnea, cough, wheezing symptoms,lung function. It is a new type ofanti-inflammatory and anti-asthmatic drugs on bronchi-al asthma, with a good clinical value.